Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorSvensson, Robin J.
dc.contributor.authorAarnoutse, Rob E.
dc.contributor.authorDiacon, Andreas H
dc.contributor.authorDawson, Rodney
dc.contributor.authorGillespie, Stephen H.
dc.contributor.authorBoeree, Martin J.
dc.contributor.authorSimonsson, Ulrika S. H.
dc.date.accessioned2017-08-08T10:30:13Z
dc.date.available2017-08-08T10:30:13Z
dc.date.issued2018-04
dc.identifier.citationSvensson , R J , Aarnoutse , R E , Diacon , A H , Dawson , R , Gillespie , S H , Boeree , M J & Simonsson , U S H 2018 , ' A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses ' , Clinical Pharmacology & Therapeutics , vol. 103 , pp. 674-683 . https://doi.org/10.1002/cpt.778en
dc.identifier.issn1532-6535
dc.identifier.otherPURE: 250351811
dc.identifier.otherPURE UUID: 38977a4b-3f44-4e09-828f-aefee6947c90
dc.identifier.otherBibtex: urn:a091c4d63187746694d462988d1d5d98
dc.identifier.otherScopus: 85043456721
dc.identifier.otherORCID: /0000-0001-6537-7712/work/39477858
dc.identifier.otherWOS: 000427114900030
dc.identifier.urihttp://hdl.handle.net/10023/11402
dc.descriptionThe research leading to these results has received funding from the Swedish Research Council in addition to the Innovative Medicines Initiative Joint Undertaking (www.imi.europe.eu) under grant agreement n°115337, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.en
dc.description.abstractAccumulating evidence suggest that increasing doses of rifampicin may shorten tuberculosis treatment. The PanACEA HIGHRIF1 trial assessed safety, pharmacokinetics and anti-mycobacterial activity of rifampicin at doses up to 40 mg/kg. Eighty-three pulmonary tuberculosis patients received 10, 20, 25, 30, 35 or 40 mg/kg rifampicin daily over 2 weeks, supplemented with standard doses of isoniazid, pyrazinamide and ethambutol in the second week. This study aimed at characterizing rifampicin pharmacokinetics observed in HIGHRIF1 using non-linear mixed effects modeling. The final population pharmacokinetic model included an enzyme turn-over model accounting for time-dependent elimination due to auto-induction, concentration-dependent clearance and dose-dependent bioavailability. The relationship between clearance and concentration was characterized by a Michaelis-Menten relationship. The relationship between bioavailability and dose was described using an Emax relationship. The model will be key in determining exposure-response relationships for rifampicin and should be considered when designing future trials and when treating future patients with high dose rifampicin.
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofClinical Pharmacology & Therapeuticsen
dc.rightsCopyright 2017 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.en
dc.subjectRifampinen
dc.subjectTuberculosisen
dc.subjectPharmacokineticsen
dc.subjectModelingen
dc.subjectNonlinear modelsen
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subject3rd-DASen
dc.subject.lccRA0421en
dc.subject.lccRMen
dc.titleA population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin dosesen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Global Health Implementation Groupen
dc.contributor.institutionUniversity of St Andrews. Gillespie Groupen
dc.contributor.institutionUniversity of St Andrews. Biomedical Sciences Research Complexen
dc.contributor.institutionUniversity of St Andrews. Infection Groupen
dc.contributor.institutionUniversity of St Andrews. Infection and Global Health Divisionen
dc.identifier.doihttps://doi.org/10.1002/cpt.778
dc.description.statusPeer revieweden
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1002/cpt.778/full#footer-support-infoen


This item appears in the following Collection(s)

Show simple item record